Canine immunotherapy Vetigenics specializes in canine-specific immune-based therapies using CANIBODIES™ derived from native canine germline genes, presenting a unique selling point for veterinary oncology and immune-related diseases in pets.

Cancer and infection focus Recent press confirms development of antibody treatments for cancer and other diseases in dogs and cats, signaling opportunities to engage veterinary oncologists, infectious disease specialists, and specialty clinics.

Seed funding momentum Seed financing of 6M plus ongoing clinical progress implies readiness to pursue partnerships or co-development deals with larger veterinary pharma companies or biotech firms seeking innovative canine targets.

Rapid modality flexibility CANIBODIES can be engineered into multiple formats (full-length canine IgGs, BiTEs, CAR-T) enabling scalable collaboration across diagnostics, therapeutics, and targeted immune-modulation programs.

Strategic partnerships Active collaboration network with animal and human health experts positions Vetigenics for co-development, licensing, or sponsored research arrangements with veterinary clinics, academia, and biotech sponsors.